Tiina Saarto

Tiina Saarto

Auto-generated profile, based on publicly available information

Tiina Saarto

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2007 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TSTiina Saarto
Tiina Saarto
PWPhilip J Wiffen
Philip J Wiffen

1 October 2004 in Acta Oncologica
Verified
Journal Article
Closed access
TSTiina Saarto
Tiina Saarto
LVLeena Vehmanen
Leena Vehmanen
PVPekka Virkkunen
Pekka Virkkunen
CBCarl Blomqvist
Carl Blomqvist
Ten-year follow-up results are presented of an adjuvant clodronate trial in patients with primary breast cancer. Between 1990 and 1993, 299 women with primary node positive breast cancer were randomized to oral clodronate 1600 mg daily (149) or controls (150) for 3 years. All patients received adjuvant chemo- or endocrine therapy. Within 10 years bone metastases were detected at the same frequency in the clodronate and control groups: 44 (32%) vs. 42 (29%), respectively, (p=0.35). The frequency of non-skeletal recurrences (visceral and local) was significantly higher in the clodronate group 69 (50%) as compared with the controls 51 (36%) (p=0.005). Ten-year disease-free survival (DFS) remained significantly lower in the clodronate group (45% vs. 58%, p=0.01, respectively). This was especially seen in oestrogen receptor negative patients (25% vs. 58%, p=0.004, respectively). No significant overall survival difference was found between the groups. As previously reported 3-year adjuvant clodronate treatment did not prevent the development of bone metastases in node-positive breast cancer patients. A negative effect of clodronate on DFS by increasing the development of visceral metastases was still seen at 10 years, but this did not significantly compromise overall survival.

20 July 2005
Verified
Reference Entry
Closed access
PDF file
TST Saarto
T Saarto
PWPj Wiffen
Pj Wiffen

11 June 2010 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
TST. Saarto
T. Saarto
PWP. J. Wiffen
P. J. Wiffen
International audienceBackground For many years antidepressant drugs have been used to manage neuropathic pain, and are often the first choice treatment. It is not clear, however, which antidepressant is more effective, what role the newer antidepressants can play in treating neuropathic pain, and what adverse effects are experienced by patients

27 September 2010 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
HPH. M. Penttinen
H. M. Penttinen
TST. Saarto
T. Saarto
PKP. Kellokumpu‐Lehtinen
P. Kellokumpu‐Lehtinen
CBC. Blomqvist
C. Blomqvist
RHR. Huovinen
R. Huovinen
LHL. Hakamies‐Blomqvist
L. Hakamies‐Blomqvist

12 October 2016 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
KRKaisa Rajala
Kaisa Rajala
JLJuho T. Lehto
Juho T. Lehto
MSM. Saarinen
M. Saarinen
ESE. Sutinen
E. Sutinen
TST. Saarto
T. Saarto
MMM. Myllärniemi
M. Myllärniemi
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with median survival from 2 to 7 years. Palliative care is an important part of patients´ care as lung transplantation is not an option for the majority of patients. The aim of this study was to describe treatment practices, decision-making and symptoms during end-of-life care of IPF patients. We identified 59 deceased patients from a national prospective IPF cohort study (FinnishIPF) and analyzed retrospectively their health care documentation during the 6 months that preceded death. Hospital was the place of death for 47 patients (80 %). A majority of the patients (93 %) were hospitalized for a mean of 30 days (range 1–96 days) during the last 6 months of their life. Altogether, patients spent 15 % of their last 6 months of life in a hospital. End-of-life decisions and do not resuscitate (DNR) orders were made for 19 (32 %) and 34 (57 %) of the patients, respectively, and 22 (42 %) of these decisions were made ≤ 3 days prior to death. During the final hospital stay, antibiotics were given to 79 % and non-invasive ventilation to 36 % of patients. During the last 24 h of life, radiologic imaging or laboratory tests were taken in 19 % and 53 % of the hospitalized patients, respectively. These tests and life prolonging therapies were more common in tertiary hospitals compared to other places of death. Dyspnea (66 %) and pain (31 %) were the most common symptoms recorded. Opioids were prescribed to 71 % of the patients during the last week before death. The majority of IPF patients died in a hospital with ongoing life-prolonging procedures until death. The frequent use of opioids is an indicator of an intention to relieve symptoms, but end-of-life decisions were still made very late. Early integrated palliative care with advance care plan could improve the end-of-life care of dying IPF patients.